SCHEMBL3496516

SCHEMBL3496516

C#Cc1cnc(Nc2cc(OC)cc(OC)c2)nc1NC1CC(C)(C)N(C)C(C)(C)C1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 2/20 0.57
BRD4 O60885 1/20 0.41
ULK1 O75385 1/20 0.41
ULK2 Q8IYT8 1/20 0.41
TYRO3 Q06418 3/20 0.39
AXL P30530 2/20 0.39
MERTK Q12866 1/20 0.39
NUAK1 O60285 1/20 0.39
IGF1R P08069 2/20 0.39
SYK P43405 3/20 0.38
EGFR P00533 2/20 0.36
FGFR1 P11362 1/20 0.36
ITK Q08881 1/20 0.36
CSNK2A2 P19784 1/20 0.35
CSNK2A1 P68400 1/20 0.35
USP2 O75604 2/20 0.35
CYP1A2 P05177 2/20 0.35
CLK4 Q9HAZ1 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3494403 0.90 PRKCQ (0.57) PRKCQBRD4ULK1ULK2NUAK1
SCHEMBL3496431 0.88 PRKCQ (0.55) PRKCQBRD4ULK1ULK2TYRO3
SCHEMBL3494481 0.86 PRKCQ (0.63) PRKCQBRD4ULK1ULK2TYRO3
SCHEMBL3496305 0.86 PRKCQ (0.60) PRKCQBRD4ULK1ULK2TYRO3
SCHEMBL3496953 0.85 PRKCQ (0.59) PRKCQBRD4ULK1ULK2TYRO3
SCHEMBL3492920 0.85 PRKCQ (0.75) PRKCQBRD4ULK1ULK2SYK
SCHEMBL3495607 0.85 PRKCQ (0.59) PRKCQBRD4ULK1ULK2EGFR
SCHEMBL3496345 0.82 ULK1 (0.62) PRKCQULK1ULK2EGFR
SCHEMBL3493830 0.80 PRKCQ (0.71) PRKCQBRD4ULK1ULK2SYK
SCHEMBL3495134 0.79 ULK1 (0.51) PRKCQBRD4ULK1IGF1RSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US claimed
US-8993585-B2 Cyclic amine substituted pyrimidinediamines as PKC inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2015-03-31 US disclosed
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. 2010-05-27 US disclosed
EP-2183225-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2010-05-12 EP disclosed
WO-2009012421-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130486-A1 CYCLIC AMINE SUBSTITUTED PYRIMIDINEDIAMINES AS PKC INHIBITORS PRKCH, PKD2, PRKCQ PRKCQ 3/4885BRD4 1173/4885ULK1 832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.